Early and very limited results from e-Therapeutics’ (LON:EXT) phase I trial of cancer drug candidate ETS2101 have so far revealed no “dose limiting toxicities” or other adverse effects.
So far, 12 patients have been given low doses of the treatment in phase I studies, which are designed to test the safety and tolerability. The amount administered will be increased over time.
Researchers are assessing two groups – one with primary or secondary brain cancer, the other with solid tumours.
The former, which will ultimately enrol 24 patients, remains on track to report its findings in the final quarter of 2103, while the latter, which will take in 45 patients, is expected to yield results in the first three months of 2014.
The company in a stock exchange statement revealed that some patients have completed “multiple cycles of treatment with ETS2101 and a number continue to be treated having received up to 11 weekly doses”.
Professor Santosh Kesari, of the Moores Cancer Center in California, is the investigator leading the brain cancer study.
He said: “We are delighted to be evaluating the novel anti-cancer agent ETS2101 at our centre.
“Though we have so far exposed patients only to relatively low doses of the drug, we are reassured that the findings to date suggest good tolerability as we move to enrol additional patients at increasing doses.”